Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: The Victimization Of Big Biotech

Early Success In Biotech Raises An Almost Impossible Bar

Executive Summary

Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.

You may also be interested in...



Roche Mounts NMOSD Challenge To Alexion’s Soliris

Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.

Stock Watch: Defeat Is The Mother Of Reinvention

Companies that are successful do not need to change their name, therapeutic area or product focus.

Stock Watch: Orphan Drug Profitability Under Threat

The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel